valentines day gsk loves peter, page-2

David Langsam, editor, Biotech Daily obviously isn't paid by Biota to produce stock reports.

"Biota (BTA): This stock thoroughly deserves to be under-rated following an abysmal 2008, capped by chairman John Grant's performance at the October annual general meeting. When asked to take responsibility for passing up a $75 million legal settlement from Glaxosmithkline, he didn't understand shareholders expected his resignation. Biota had $60 million in cash on June 30 and its market cap of $75 million effectively valued its future Relenza royalties, staff, pipeline of six or more drugs and assets at little more than nothing."


http://www.theaustralian.news.com.au/story/0,25197,24984864-5001942,00.html

I'm pretty certain Peter Cook's clueless performance at the mediation meeting would have blown John Grant's clueless performance at the AGM out of the water.

Comrades in cluelessness (and running Biota into the ground while sucking it dry).